Generic placeholder image

Current Cancer Drug Targets

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

The Novel RARβ Isoform (β 5) is a Potential Target of Retinoids in Breast Cancer

Author(s): Konstantin Christov

Volume 9 , Issue 2 , 2009

Page: [142 - 147] Pages: 6

DOI: 10.2174/156800909787580953

Price: $65

Abstract

Retinoic acid receptor beta 2 (RARβ2) isoform has been considered a putative tumor suppressor because it is expressed in normal cells but is lacking in most tumors, including breast cancer. Recently, we identified a novel RARβ isoform (β5) in breast cancer cells, which may sereve as a potential target of retinoids in cancer prevention and therapy studies. In this review are summarized the data on the expression of RARβ5 and of the previously identified RARβ4 and RARβ isoforms in various breast cancer cell lines. We found that RARβ5 may serve as a potential biomarker of resistance of breast cancer cells to retinoids and thus may have clinical implication in selecting patients that may benefit the most from clinical trials with retinoids.

Keywords: Retinoids, retinoid receptors, RARβ5 isoform, breast cancer, prevention


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy